Erakusten 1 - 5 emaitzak -- 5 bilaketa honetara 'Seyed Reza Mousavi (13223324)', Bilaketaren denbora: 0,01s Findu emaitzak
  1. 1
    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.

    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites. nork Seyed Reza Mousavi (13223324)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].

    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58]. nork Seyed Reza Mousavi (13223324)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.

    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. nork Seyed Reza Mousavi (13223324)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites. nork Seyed Reza Mousavi (13223324)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites. nork Seyed Reza Mousavi (13223324)

    Argitaratua 2025
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: